Safety and efficacy of uninterrupted periprocedural apixaban in patients undergoing atrial fibrillation catheter ablation

A metaanalysis of 1,057 patients

Jalaj Garg, Rahul Chaudhary, Parasuram Krishnamoorthy, Neeraj Shah, Babak Bozorgnia, Andrea Natale

Research output: Contribution to journalReview article

Abstract

Apixaban (factor Xa inhibitor) is a novel anticoagulant and may be beneficial during atrial fibrillation (AF) ablation for prevention of thromboembolic events. However, the adverse effects of periprocedural apixaban therapy have not been thoroughly evaluated. A meta-analysis was performed to evaluate the safety of apixaban for anticoagulation in AF ablation. We searched the online databases till October 2015 for studies comparing Apixaban with Vitamin K antagonists in atrial fibrillation patients undergoing catheter ablation. Primary outcome of our study was composite of thromboembolic event and bleeding (includes major and minor bleeding). A total of 1,057 atrial fibrillation patients in 3 studies undergoing catheter ablation were included in this analysis. Zero thromboembolic events were reported in the apixaban group and 1 in the VKA group with no statistical difference (OR 0.75; 95% CI 0.03-18.49). No major differences were observed for the primary outcome (OR 0.92; 95% CI 0.54-1.55), risk of overall bleeding (OR 0.94, 95% CI 0.55- 1.58), major bleeding (OR1.37; 95% CI 0.33-5.67), minor bleeding (OR 0.89; 95% CI 0.50-1.55), pericardial effusion (OR 0.50; 95% CI 0.18-1.38) and groin hematoma (OR 1.36; 95% CI 0.70-2.65). Uninterrupted apixaban administration in patients undergoing AF catheter ablation was non-inferior to VKA without increasing the risk of major and minor bleeding.

Original languageEnglish (US)
Pages (from-to)66-68
Number of pages3
JournalJournal of Atrial Fibrillation
Volume8
Issue number6
StatePublished - Apr 1 2016

Fingerprint

Catheter Ablation
Atrial Fibrillation
Hemorrhage
Safety
Pericardial Effusion
Vitamin K
Groin
Hematoma
Anticoagulants
Meta-Analysis
apixaban
Outcome Assessment (Health Care)
Databases

Keywords

  • Anticoagulation
  • Apixaban
  • Atrial fibrillation ablation
  • Complications

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Safety and efficacy of uninterrupted periprocedural apixaban in patients undergoing atrial fibrillation catheter ablation : A metaanalysis of 1,057 patients. / Garg, Jalaj; Chaudhary, Rahul; Krishnamoorthy, Parasuram; Shah, Neeraj; Bozorgnia, Babak; Natale, Andrea.

In: Journal of Atrial Fibrillation, Vol. 8, No. 6, 01.04.2016, p. 66-68.

Research output: Contribution to journalReview article

Garg, Jalaj ; Chaudhary, Rahul ; Krishnamoorthy, Parasuram ; Shah, Neeraj ; Bozorgnia, Babak ; Natale, Andrea. / Safety and efficacy of uninterrupted periprocedural apixaban in patients undergoing atrial fibrillation catheter ablation : A metaanalysis of 1,057 patients. In: Journal of Atrial Fibrillation. 2016 ; Vol. 8, No. 6. pp. 66-68.
@article{f5b6ef65cb684f3c824e73c127771b8f,
title = "Safety and efficacy of uninterrupted periprocedural apixaban in patients undergoing atrial fibrillation catheter ablation: A metaanalysis of 1,057 patients",
abstract = "Apixaban (factor Xa inhibitor) is a novel anticoagulant and may be beneficial during atrial fibrillation (AF) ablation for prevention of thromboembolic events. However, the adverse effects of periprocedural apixaban therapy have not been thoroughly evaluated. A meta-analysis was performed to evaluate the safety of apixaban for anticoagulation in AF ablation. We searched the online databases till October 2015 for studies comparing Apixaban with Vitamin K antagonists in atrial fibrillation patients undergoing catheter ablation. Primary outcome of our study was composite of thromboembolic event and bleeding (includes major and minor bleeding). A total of 1,057 atrial fibrillation patients in 3 studies undergoing catheter ablation were included in this analysis. Zero thromboembolic events were reported in the apixaban group and 1 in the VKA group with no statistical difference (OR 0.75; 95{\%} CI 0.03-18.49). No major differences were observed for the primary outcome (OR 0.92; 95{\%} CI 0.54-1.55), risk of overall bleeding (OR 0.94, 95{\%} CI 0.55- 1.58), major bleeding (OR1.37; 95{\%} CI 0.33-5.67), minor bleeding (OR 0.89; 95{\%} CI 0.50-1.55), pericardial effusion (OR 0.50; 95{\%} CI 0.18-1.38) and groin hematoma (OR 1.36; 95{\%} CI 0.70-2.65). Uninterrupted apixaban administration in patients undergoing AF catheter ablation was non-inferior to VKA without increasing the risk of major and minor bleeding.",
keywords = "Anticoagulation, Apixaban, Atrial fibrillation ablation, Complications",
author = "Jalaj Garg and Rahul Chaudhary and Parasuram Krishnamoorthy and Neeraj Shah and Babak Bozorgnia and Andrea Natale",
year = "2016",
month = "4",
day = "1",
language = "English (US)",
volume = "8",
pages = "66--68",
journal = "Journal of Atrial Fibrillation",
issn = "1941-6911",
publisher = "Cardiofront, Inc.",
number = "6",

}

TY - JOUR

T1 - Safety and efficacy of uninterrupted periprocedural apixaban in patients undergoing atrial fibrillation catheter ablation

T2 - A metaanalysis of 1,057 patients

AU - Garg, Jalaj

AU - Chaudhary, Rahul

AU - Krishnamoorthy, Parasuram

AU - Shah, Neeraj

AU - Bozorgnia, Babak

AU - Natale, Andrea

PY - 2016/4/1

Y1 - 2016/4/1

N2 - Apixaban (factor Xa inhibitor) is a novel anticoagulant and may be beneficial during atrial fibrillation (AF) ablation for prevention of thromboembolic events. However, the adverse effects of periprocedural apixaban therapy have not been thoroughly evaluated. A meta-analysis was performed to evaluate the safety of apixaban for anticoagulation in AF ablation. We searched the online databases till October 2015 for studies comparing Apixaban with Vitamin K antagonists in atrial fibrillation patients undergoing catheter ablation. Primary outcome of our study was composite of thromboembolic event and bleeding (includes major and minor bleeding). A total of 1,057 atrial fibrillation patients in 3 studies undergoing catheter ablation were included in this analysis. Zero thromboembolic events were reported in the apixaban group and 1 in the VKA group with no statistical difference (OR 0.75; 95% CI 0.03-18.49). No major differences were observed for the primary outcome (OR 0.92; 95% CI 0.54-1.55), risk of overall bleeding (OR 0.94, 95% CI 0.55- 1.58), major bleeding (OR1.37; 95% CI 0.33-5.67), minor bleeding (OR 0.89; 95% CI 0.50-1.55), pericardial effusion (OR 0.50; 95% CI 0.18-1.38) and groin hematoma (OR 1.36; 95% CI 0.70-2.65). Uninterrupted apixaban administration in patients undergoing AF catheter ablation was non-inferior to VKA without increasing the risk of major and minor bleeding.

AB - Apixaban (factor Xa inhibitor) is a novel anticoagulant and may be beneficial during atrial fibrillation (AF) ablation for prevention of thromboembolic events. However, the adverse effects of periprocedural apixaban therapy have not been thoroughly evaluated. A meta-analysis was performed to evaluate the safety of apixaban for anticoagulation in AF ablation. We searched the online databases till October 2015 for studies comparing Apixaban with Vitamin K antagonists in atrial fibrillation patients undergoing catheter ablation. Primary outcome of our study was composite of thromboembolic event and bleeding (includes major and minor bleeding). A total of 1,057 atrial fibrillation patients in 3 studies undergoing catheter ablation were included in this analysis. Zero thromboembolic events were reported in the apixaban group and 1 in the VKA group with no statistical difference (OR 0.75; 95% CI 0.03-18.49). No major differences were observed for the primary outcome (OR 0.92; 95% CI 0.54-1.55), risk of overall bleeding (OR 0.94, 95% CI 0.55- 1.58), major bleeding (OR1.37; 95% CI 0.33-5.67), minor bleeding (OR 0.89; 95% CI 0.50-1.55), pericardial effusion (OR 0.50; 95% CI 0.18-1.38) and groin hematoma (OR 1.36; 95% CI 0.70-2.65). Uninterrupted apixaban administration in patients undergoing AF catheter ablation was non-inferior to VKA without increasing the risk of major and minor bleeding.

KW - Anticoagulation

KW - Apixaban

KW - Atrial fibrillation ablation

KW - Complications

UR - http://www.scopus.com/inward/record.url?scp=84975880614&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84975880614&partnerID=8YFLogxK

M3 - Review article

VL - 8

SP - 66

EP - 68

JO - Journal of Atrial Fibrillation

JF - Journal of Atrial Fibrillation

SN - 1941-6911

IS - 6

ER -